Mobile Site ›
Normal View

Test ID: FBLP
B-Cell Lymphoma, FISH, Blood or Bone Marrow

Secondary ID A test code used for billing and in test definitions created prior to November 2011

88897

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Useful For Suggests clinical disorders or settings where the test may be helpful

Detecting an abnormal clone associated with the common chromosome anomalies seen in patients with B-cell lymphoma, specifically Burkitt, mantle cell, follicular, diffuse large B-cell, and MALT lymphoma

 

Individual probes can also be utilized to identify specific chromosome anomalies in patients with B-cell lymphoma and track the response to therapy.

Reflex Tests Lists test(s) that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial test(s)

Test IDReporting NameAvailable SeparatelyAlways Performed
ADD1FOne Additional FISH ProbeNoNo
ADD2FTwo Additional FISH ProbesNoNo
ADD4FFour Additional FISH ProbesNoNo
ADD3FThree Additional FISH ProbesNoNo
ADD5FFive Additional FISH ProbesNoNo
ADD6FSix Additional FISH ProbesNoNo
ADD7FSeven Additional FISH ProbesNoNo
ADD8FEight Additional FISH ProbesNoNo
ADD9FNine Additional FISH ProbesNoNo
ADD10Ten Additional FISH ProbesNoNo
ADD11Eleven Additional FISH ProbesNoNo
ADD12Twelve Additional FISH ProbesNoNo
14FPFourteen Additional FISH ProbesNoNo
13FPThirteen Additional FISH ProbesNoNo
15FPFifteen Additional FISH ProbesNoNo
16FPSixteen Additional FISH ProbesNoNo
17FPSeventeen Additional FISH ProbesNoNo
18FPEighteen Additional FISH ProbesNoNo
19FPNineteen Additional FISH ProbesNoNo
20FPTwenty Additional FISH ProbesNoNo
21FPTwenty One Additional FISH ProbesNoNo
22FPTwenty Two Additional FISH ProbesNoNo
23FPTwenty Three Additional FISH ProbesNoNo
24FPTwenty Four Additional FISH ProbesNoNo
25FPTwenty Five Additional FISH ProbesNoNo
26FPTwenty Six Additional FISH ProbesNoNo
27FPTwenty Seven Additional FISH ProbesNoNo
28FPTwenty Eight Additional FISH ProbesNoNo
29FPTwenty Nine Additional FISH ProbesNoNo
30FPThirty Additional FISH ProbesNoNo

Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.

Indicate which subtype of B-cell lymphoma is suspected as well as which anomalies need to be investigated from the following profile.

 

t(8;14), MYC/IGH

t(8q24.1;var), MYC

t(11;14), CCND1/IGH

t(11;18), BIRC3/MALT1

t(14;18), IGH/MALT1

t(14;18), IGH/BCL2

t(3q27;var), BCL6

t(8;22), MYC/IGL

 

If the patient is being tracked for known anomalies, indicate which anomalies need to be investigated.

 

The number of probes ordered will determine the price of the testing. When this test is ordered, a charge for 2 FISH probes and interpretation is included. If additional probes or the entire panel are ordered, additional probes charges will be added.

 

See Malignant Lymphoma, Guideline for Bone Marrow Staging Studies in Special Instructions

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test

Method Name A short description of the method used to perform the test

Fluorescence In Situ Hybridization (FISH)

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

B-Cell Lymphoma, FISH, B/BM

Aliases Lists additional common names for a test, as an aid in searching

3q27
8;22 translocation
API2/MALT1
B Cell
BCL2/IGH
BCL6
BIRC3
BIRC3/MALT1
Burkitt Lymphoma
c-MYC/IGH
c-MYC/IGL
c-MYC/Lambda
CCND1/IGH
Cyclin D1
Diffuse Large Cell Lymphoma
ENMZL
FMCL
Follicular Lymphoma
IGH/MALT1
IGL
Lambda
MALT Lymphoma
MALT1
Mantle Cell Lymphoma (MCL) (FISH)
Marginal Zone Lymphoma
MCL (Mantle Cell Lymphoma) FISH
MYC
MYC/IGH
MYC/IGL
MYC/Lambda
t(11;14)
t(11;18)
t(14;18)
t(2;8)
t(8;14)
t(8;22)
Translocation 11;14
Translocation 11;18
Translocation 14;18
Translocation 2;8
Translocation 8;14
Translocation 8;22

Specimen Type Describes the specimen type needed for testing

Varies

Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.

Provide a reason for referral with each specimen. The laboratory will not reject testing if this information is not provided, but appropriate testing and interpretation may be compromised or delayed.

 

Forms:

1. Cytogenetics Hematologic FISH Panel Patient Information Sheet (Supply T603) in Special Instructions

2. If not ordering electronically, submit a Cytogenetics Hematologic Disorders Request Form (Supply T607) with the specimen.

 

Advise Express Mail or equivalent if not on courier service.

 

Submit only 1 of the following specimens:

 

Preferred:

Specimen Type: Blood

Container/Tube: Green top (sodium heparin)

Specimen Volume: 7-10 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Other anticoagulants are not recommended and are harmful to the viability of the cells.

                                                                                                                                                          

Specimen Type: Bone marrow

Container/Tube: Green top (sodium heparin)

Specimen Volume: 1-2 mL

Collection Instructions:

1. Invert several times to mix bone marrow.

2. Other anticoagulants are not recommended and are harmful to the viability of the cells.

 

Acceptable:

Specimen Type: Touch prep or fresh tissue

Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.

Blood: 2 mL/Bone Marrow: 1 mL

Reject Due To Identifies specimen types and conditions that may cause the specimen to be rejected

Hemolysis

NA

Lipemia

NA

Icterus

NA

Other

Clotted blood or bone marrow

Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.

Specimen TypeTemperatureTime
VariesAmbient (preferred)
 Refrigerated 

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Lymphoid neoplasms are known to be complex and the prognosis and clinical course of patients with lymphoma is highly variable. Genetic abnormalities have emerged as 1 of the most reliable criteria for categorizing lymphomas. Several chromosome anomalies and variants of these anomalies have been associated with various kinds of lymphoma (see Table). 

Common chromosome anomalies in lymphomas

Lymphoma Type

Chromosome Anomaly

FISH Probe

Burkitt

t(8;14)(q24;q32)

MYC/IGH

t(8;22)(q24;q11.2)

MYC/IGL

t(22;var)(q11.2;var)

IGL

Mantle cell

t(11;14)(q13;q32)

CCND1-XT/IGH

Follicular

t(14;18)(q32;q21)

IGH/BCL2

Diffuse large B-cell

t(3;var)(q27;var)

BCL6

t(14;18)(q32;q21)

IGH/BCL2

t(8;14)(q24;q32)

MYC/IGH

t(8;22)(q24;q11.2)

MYC/IGL

t(22;var)(q11.2;var)

IGL

Marginal zone of

MALT type

t(11;18)(q21;q21)

BIRC3/MALT1

t(14;18)(q32;q21)

IGH/MALT1

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

An interpretive report will be provided.

Interpretation Provides information to assist in interpretation of the test results

A neoplastic clone is detected when the percent of cells with an abnormality exceeds the normal reference range for any given probe.

 

The absence of an abnormal clone does not rule the presence of neoplastic disorder.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

This test is not approved by the FDA and it is best used as an adjunct to existing clinical and pathologic information.

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

1. Remstein ED, Kurtin PJ, Buno I, et al: Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma. Br J Haematol 2000 Sep;110(4):856-862

2. Remstein ED, Kurtin PJ, James CD, et al: Mucosa-associated lymphoid tissue lymphomas with t(11;18) (q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathways. Am J Pathol 2002 Jul;161(1):63-71

3. Remstein ED, Dogan A, Einerson RR, et al: The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 2006 Dec;30(12):1546-1553H636

Method Description Describes how the test is performed and provides a method-specific reference

Anomalies involving BCL6, c-MYC, and IGL are detected using a break-apart FISH probe. If a MYC abnormality is detected, reflex testing will be performed to identify the translocation partner. Translocations involving fusion of CCND1 and IGH; BCL2 and IGH; MYC and IGH; BIRC3 and MALT1; IGH and MALT1; and MYC and IGL are detected using dual-color, dual-fusion (D-FISH) strategies. A total of 200 nuclei are scored for the break-apart probe set. For each D-FISH probe set, 500 interphase nuclei are scored and results for each abnormal probe(s) are expressed as percent abnormal nuclei.(Brockman SR, Paternoster SF, Ketterling RP, et al: New highly sensitive fluorescence in situ hybridization method to detect PML/RARA fusion in acute promyelocytic leukemia. Cancer Genet Cytogenet 2003;145:144-51)

Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.

Monday through Friday; 6 a.m.-9 p.m., Saturday, Sunday; 6 a.m.-4 p.m.

Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.

7 days

Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result

10 days

Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

Indefinitely

Performing Laboratory Location The location of the laboratory that performs the test

Rochester

Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.

This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

B-Cell Lymphoma, FISH, Blood or Bone Marrow

88271 x 2-DNA probe, each

88275 x 2-Interphase in situ hybridization

88291-Interpretation and report

 

One Additional FISH Probe

88271-DNA probe, each (if appropriate)

88275-Interphase in situ hybridization (if appropriate)

 

Two Additional FISH Probes

88271 x 2-DNA probe, each (if appropriate)

88275-Interphase in situ hybridization (if appropriate)

 

Three Additional FISH Probes

88271 x 3-DNA probe, each (if appropriate)

88275-Interphase in situ hybridization (if appropriate)

 

Four Additional FISH Probes

88271 x 4-DNA probe, each (if appropriate)

88275 x 2-Interphase in situ hybridization (if appropriate)

 

Five Additional FISH Probes

88271 x 5-DNA probe, each (if appropriate)

88275 x 2-Interphase in situ hybridization (if appropriate)

 

Six Additional FISH Probes

88271 x 6-DNA probe, each (if appropriate)

88275 x 3-Interphase in situ hybridization (if appropriate)

 

Seven Additional FISH Probes

88271 x 7-DNA probe, each (if appropriate)

88275 x 3-Interphase in situ hybridization (if appropriate)

 

Eight Additional FISH Probes

88271 x 8-DNA probe, each (if appropriate)

88275 x 4-Interphase in situ hybridization (if appropriate)

 

Nine Additional FISH Probes

88271 x 9-DNA probe, each (if appropriate)

88275 x 4-Interphase in situ hybridization (if appropriate)

 

Ten Additional FISH Probes

88271 x 10-DNA probe, each (if appropriate)

88275 x 5-Interphase in situ hybridization (if appropriate)

 

Eleven Additional FISH Probes

88271 x 11-DNA probe, each (if appropriate)

88275 x 5-Interphase in situ hybridization (if appropriate)

 

Twelve Additional FISH Probes

88271 x 12-DNA probe, each (if appropriate)

88275 x 6-Interphase in situ hybridization (if appropriate)

 

Thirteen Additional FISH Probes

88271 x 13-DNA probe, each (if appropriate)

88275 x 6-Interphase in situ hybridization (if appropriate)

 

Fourteen Additional FISH Probes

88271 x 14-DNA probe, each (if appropriate)

88275 x 7-Interphase in situ hybridization (if appropriate)

 

Fifteen Additional FISH Probes

88271 x 15-DNA probe, each (if appropriate)

88275 x 7-Interphase in situ hybridization (if appropriate)

 

Sixteen Additional FISH Probes

88271 x 16-DNA probe, each (if appropriate)

88275 x 8-Interphase in situ hybridization (if appropriate)

 

Seventeen Additional FISH Probes

88271 x 17-DNA probe, each (if appropriate)

88275 x 8-Interphase in situ hybridization (if appropriate)

 

Eighteen Additional FISH Probes

88271 x 18-DNA probe, each (if appropriate)

88275 x 9-Interphase in situ hybridization (if appropriate)

 

Nineteen Additional FISH Probes

88271 x 19-DNA probe, each (if appropriate)

88275 x 9-Interphase in situ hybridization (if appropriate)

 

Twenty Additional FISH Probes

88271 x 20-DNA probe, each (if appropriate)

88275 x 10-Interphase in situ hybridization (if appropriate)

 

Twenty One Additional FISH Probes

88271 x21-DNA probe, each (if appropriate)

88275 x10-Interphase in situ hybridization (if appropriate)

 

Twenty Two Additional FISH Probes

88271 x22-DNA probe, each (if appropriate)

88275 x11-Interphase in situ hybridization (if appropriate)

 

Twenty Three Additional FISH Probes

88271 x23-DNA probe, each (if appropriate)

88275 x11-Interphase in situ hybridization (if appropriate)

 

Twenty Four Additional FISH Probes

88271 x24-DNA probe, each (if appropriate)

88275 x12-Interphase in situ hybridization (if appropriate)

 

Twenty Five Additional FISH Probes

88271 x25-DNA probe, each (if appropriate)

88275 x12-Interphase in situ hybridization (if appropriate)

 

Twenty Six Additional FISH Probes

88271 x26-DNA probe, each (if appropriate)

88275 x13-Interphase in situ hybridization (if appropriate)

 

Twenty Seven Additional FISH Probes

88271 x27-DNA probe, each (if appropriate)

88275 x13-Interphase in situ hybridization (if appropriate)

 

Twenty Eight Additional FISH Probes

88271 x28-DNA probe, each (if appropriate)

88275 x14-Interphase in situ hybridization (if appropriate)

 

Twenty Nine Additional FISH Probes

88271 x29-DNA probe, each (if appropriate)

88275 x14-Interphase in situ hybridization (if appropriate)

 

Thirty Additional FISH Probes

88271 x30-DNA probe, each (if appropriate)

88275 x15-Interphase in situ hybridization (if appropriate)

LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.

Result IDReporting NameLOINC Code
27185Specimen31208-2
27186Specimen IDIn Process
G_701SourceN/A
27188Order DateN/A
G_703Reason For Referral42349-1
27190Method49549-9
27191ResultIn Process
27192Interpretation69965-2
27193AmendmentIn Process
27194ConsultantIn Process
27195Released DateN/A